Intermittent treatment of BRAF(V600E) melanoma cells delays resistance by adaptive resensitization to drug rechallenge

Patients with melanoma receiving drugs targeting BRAF(V600E) and mitogen-activated protein (MAP) kinase kinases 1 and 2 (MEK1/2) invariably develop resistance and face continued progression. Based on preclinical studies, intermittent treatment involving alternating periods of drug withdrawal and rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavran, Andrew J., Stuart, Scott A., Hayashi, Kristyn R., Basken, Joel M., Brandhuber, Barbara J., Ahn, Natalie G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944661/
https://www.ncbi.nlm.nih.gov/pubmed/35290123
http://dx.doi.org/10.1073/pnas.2113535119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944661/
https://www.ncbi.nlm.nih.gov/pubmed/35290123
http://dx.doi.org/10.1073/pnas.2113535119

Ejemplares similares